Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.79 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 9/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.51 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.51 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633388 | 1.00 | MEN1 (0.79) | MEN1KMT2ANR1H4MAPTLMNA | |
| SCHEMBL935186 | 0.89 | MEN1 (1.00) | MEN1KMT2ANR1H4MAPTLMNA | |
| Benzene SCHEMBL27988126 | 0.89 | MEN1 (1.00) | MEN1KMT2ANR1H4MAPTLMNA | |
| SCHEMBL1682175 | 0.87 | MEN1 (0.59) | MEN1KMT2ANR1H4MAPTLMNA | |
| SCHEMBL1682173 | 0.87 | MEN1 (0.59) | MEN1KMT2ANR1H4MAPTLMNA | |
| Butane SCHEMBL6828046 | 0.85 | MEN1 (0.93) | MEN1KMT2ANR1H4MAPTLMNA | |
| SCHEMBL4142686 | 0.85 | NR1H4 (0.56) | MEN1KMT2ANR1H4MAPTLMNA | |
| SCHEMBL4142682 | 0.85 | NR1H4 (0.56) | MEN1KMT2ANR1H4MAPTLMNA | |
| SCHEMBL3181515 | 0.85 | MAPT (0.78) | MEN1KMT2ANR1H4MAPTLMNA | |
| SCHEMBL3181512 | 0.85 | MAPT (0.78) | MEN1KMT2ANR1H4MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932403-B2 | Process for preparing pyrrole derivatives and intermediates | RATIOPHARM GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20090012312-A1 | Process for Preparing Pyrrole Derivatives and Intermediates | RATIOPHARM GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| WO-2007131528-A1 | PROCESS FOR PREPARING C5 INTERMEDIATES AND THEIR USE IN THE PREPARATION OF N-SUBSTITUTED PYRROLE DERIVATIVES | RATIOPHARM GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| EP-1705175-A1 | Process for preparing C5 products and their use for Atorvastatin synthesis | ratiopharm GmbH (DE) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006066823-A1 | PROCESS FOR PREPARING PYRROLE DERIVATIVES AND INTERMEDIATES | RATIOPHARM GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1671947-A1 | Process for preparing pyrrole derivatives and intermediates | Ratiopharm GmbH (DE) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012312-A1 | Process for Preparing Pyrrole Derivatives and Intermediates | DHCR7, DHPS, CYP46A1 | MEN1 1533/4885KMT2A 3515/4885NR1H4 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.